Using the CAROL device to treat early stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new device called the CAROL that uses heat to destroy small lung tumors during surgery. It is for people with a specific type of early-stage lung cancer (stage 1, tumor 2 cm or smaller) that is located in the outer part of the lung and can be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC) with one tumor that is 2 cm or smaller.
- The tumor is located in the outer one-third of the lung (close to the edge).
- You are a candidate for a lobectomy (surgery to remove a lobe of the lung).
- You do not have another lung tumor or certain other lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This trial tests combining tumor ablation with the immunotherapy drug tislelizumab and chemotherapy before surgery for people with stage II–IIIB non-small cell lung cancer. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
This trial compares two treatments for early-stage lung cancer: a lung-saving procedure using heat to destroy the tumor (bronchoscopic microwave ablation) versus surgery to remove it. It aims to see which approach is better for people whose lung function may be limited.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.